A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)

NCT00336713 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder

Interventions

DRUG: Saredutant (SR48968C)
DRUG: Placebo

Sponsor

Sanofi